AbbVie Inc (AbbVie) is a specialty biopharmaceutical company which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its pharmaceuticals are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various cancer types, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, Women's Health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses across the world. AbbVie is headquartered in North Chicago, Illinois, the US.
Headquarters
United States of America
Address
1 N Waukegan Rd, North Chicago, Illinois, 60064-1802
Website
www.abbvie.com
Telephone
1 847 9327900
No of Employees
50,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABBV (NYSE)
Revenue (2021)
$56.2B
22.7%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
150%
(2021 vs 2020)
Market Cap*
$260.8B
Net Profit Margin (2021)
XXX
103.8%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Products for treating Autoimmune Diseases: | HUMIRA |
| Rheumatoid Arthritis | RINVOQ |
| Psoriatic Arthritis | SKYRIZI |
| XXX | XXX |
| XXX | XXX |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | New Products/Services | In June, the company launched new data sharing platform to connect real-world health data to clinical research. |
| 2022 | Regulatory Approval | In June, the company secured FDA approval for SKYRIZI for the treatment of adults with moderately to severely active Crohn's disease. |
| 2022 | Contracts/Agreements | In June, the company entered into a partnership with Sirona Biochem to develop and commercialize topical skin care treatments based on active ingredients. |
Competitor Comparison
| Key Parameters | AbbVie Inc | Johnson & Johnson | Pfizer Inc | F. Hoffmann-La Roche Ltd | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | Switzerland |
| City | North Chicago | New Brunswick | New York | Basel | Basel |
| State/Province | Illinois | New Jersey | New York | - | - |
| No. of Employees | 50,000 | 141,700 | 79,000 | 100,920 | 110,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard A. Gonzalez | Chief Executive Officer; Chairman | Executive Board | 2013 | 68 |
| Robert A. Michael | Vice Chairman - Finance and Commercial Operations; Chief Financial Officer | Senior Management | 2018 | 51 |
| Henry O. Gosebruch | Chief Strategy Officer; Executive Vice President | Senior Management | 2015 | 49 |
| Laura J. Schumacher | Chief Legal Officer; Vice Chairman - External Affairs | Senior Management | 2018 | 58 |
| Timothy J. Richmond | Executive Vice President; Chief Human Resources Officer | Senior Management | 2018 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer